Dili is rare amongst patients without liver metastases receiving cancer treatment in Iceland: a population-based cohort study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationBjörnsson HK, Sverrisdottir A, Björnsson ES. Dili is rare amongst patients without liver metastases receiving cancer treatment in Iceland: a population-based cohort study [published online ahead of print, 2022 Feb 9]. Scand J Gastroenterol. 2022;1-6. doi:10.1080/00365521.2022.2038260
AbstractBackground: There is limited information on the frequency of idiosyncratic drug-liver injury (DILI) among cancer patients. The aim of the study was to evaluate the frequency of DILI due to cancer treatment in a population-based setting. Material and methods: All patients diagnosed with genitourinary cancer, breast cancer or metastatic malignant melanoma in 2007-2018 were matched with a database containing laboratory results for all major hospitals in Iceland. Medical chart review was performed for cases with ALT/AST ≥5× upper limit of normal (ULN), ALP ≥2× ULN or bilirubin ≥2× ULN. Patients with liver-, and/or bone metastases and isolated elevations of ALP and patients with other etiologies of liver enzyme elevations were excluded. Cases with a RUCAM score of probable or highly probable were included. Results: Among 4956 patients, 840 patients had liver enzyme elevations. Overall, nine (0.2%) cases of DILI were identified, seven women (78%), median age 59 years (IQR 52-66). Four patients had kidney cancer, four breast cancer and one metastatic prostate cancer. In eight cases, a single agent was implicated: Pazopanib (n = 3), axitinib, docetaxel, gemcitabine, letrozole and paclitaxel. In all cases, the treatment was interrupted or discontinued due to the liver injury. No patient developed jaundice or liver failure and no death was linked to DILI. Time to normalization of liver enzymes was 17 days (IQR 25-120). Conclusion: DILI was found to be rare and no cases of severe liver injury occurred. However, approximately 90% of patients switched to another treatment which might have affected prognosis. Keywords: DILI; RUCAM; hepatotoxicity; liver enzymes; malignancy.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- Liver injury caused by oral anticoagulants: A population-based retrospective cohort study.
- Authors: Björnsson HK, Gudmundsson DO, Björnsson ES
- Issue date: 2020 Aug
- Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.
- Authors: Xu HM, Chen Y, Xu J, Zhou Q
- Issue date: 2012 Nov 7
- Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
- Authors: Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Cáliz I, González-Jimenez A, Ulzurrun E, Gonzalez AF, Fernandez MC, Romero-Gómez M, Jimenez-Perez M, Bruguera M, Prieto M, Bessone F, Hernandez N, Arrese M, Andrade RJ, Spanish DILI Registry., SLatinDILI Network., Safer and Faster Evidence-based Translation Consortium.
- Issue date: 2014 Jul
- Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
- Authors: Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH
- Issue date: 2018 Mar 28
- Impact of SLCO1B1*5 on Flucloxacillin and Co-Amoxiclav-Related Liver Injury.
- Authors: Alshabeeb M, Alomar FA, Khan A
- Issue date: 2022